ATE403431T1 - Benzimidazolon-verbindungen - Google Patents

Benzimidazolon-verbindungen

Info

Publication number
ATE403431T1
ATE403431T1 AT02764243T AT02764243T ATE403431T1 AT E403431 T1 ATE403431 T1 AT E403431T1 AT 02764243 T AT02764243 T AT 02764243T AT 02764243 T AT02764243 T AT 02764243T AT E403431 T1 ATE403431 T1 AT E403431T1
Authority
AT
Austria
Prior art keywords
benzimidazolone compounds
compounds
benzimidazolone
analgetics
formula
Prior art date
Application number
AT02764243T
Other languages
German (de)
English (en)
Inventor
R Goehring
Zhengming Chen
Donald Kyle
Sam Victory
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE403431T1 publication Critical patent/ATE403431T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02764243T 2001-04-18 2002-04-18 Benzimidazolon-verbindungen ATE403431T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28466501P 2001-04-18 2001-04-18

Publications (1)

Publication Number Publication Date
ATE403431T1 true ATE403431T1 (de) 2008-08-15

Family

ID=23091051

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02764243T ATE403431T1 (de) 2001-04-18 2002-04-18 Benzimidazolon-verbindungen
AT08011371T ATE456564T1 (de) 2001-04-18 2002-04-18 Octahydrobenzimidazolon-verbindungen als analgetika

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08011371T ATE456564T1 (de) 2001-04-18 2002-04-18 Octahydrobenzimidazolon-verbindungen als analgetika

Country Status (13)

Country Link
US (2) US6872733B2 (enExample)
EP (3) EP1975164B1 (enExample)
JP (1) JP4401076B2 (enExample)
AT (2) ATE403431T1 (enExample)
AU (1) AU2002338424B2 (enExample)
CA (1) CA2444489C (enExample)
CY (2) CY1108456T1 (enExample)
DE (2) DE60235274D1 (enExample)
DK (2) DK1975164T3 (enExample)
ES (2) ES2340441T3 (enExample)
PT (2) PT1385518E (enExample)
SI (2) SI1385518T1 (enExample)
WO (1) WO2002085361A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1491212E (pt) * 2002-03-29 2012-11-16 Mitsubishi Tanabe Pharma Corp Medicamento para distúrbios de sono
AU2005228410A1 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100028339A1 (en) * 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) * 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
KR101374458B1 (ko) * 2005-09-30 2014-03-17 글락소 그룹 리미티드 Ｍ１ 수용체에서 활성을 갖는 화합물 및 그의 의약적 용도
JP5209479B2 (ja) * 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類
EP1960389B1 (en) * 2005-09-30 2012-08-15 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
NZ578078A (en) 2007-01-16 2011-11-25 Purdue Pharma Lp Heterocyclic-substituted piperidine as orl-1 ligands
GB0706188D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
TWI448289B (zh) 2007-08-31 2014-08-11 Purdue Pharma Lp 經取代之喹啉型哌啶化合物及其用途
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
UA99540C2 (ru) 2008-07-21 2012-08-27 Пердью Фарма Л.П. Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
WO2014102590A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
PE20190403A1 (es) 2016-07-29 2019-03-13 Janssen Pharmaceutica Nv Metodos para tratar el cancer de prostata

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
US3325499A (en) 1964-11-02 1967-06-13 Mcneilab Inc 1-(1-hydrocarbyl-4-piperdyl)-2-indolinone
DE2609645A1 (de) 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim Aminoalkylheterocyclen
US4329353A (en) 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
US4410528A (en) 1980-05-16 1983-10-18 Kyowa Hakko Kogyo Co., Ltd. Hypotensive piperidine derivatives
JPS58180481A (ja) 1982-04-15 1983-10-21 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS60120872A (ja) 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
AU688498B2 (en) 1994-04-14 1998-03-12 Merck & Co., Inc. Alpha1c adrenergic receptor antagonists
FR2722190B1 (fr) 1994-07-05 1996-10-04 Sanofi Sa Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
US5767118A (en) 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5574044A (en) 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
JPH11507670A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
DE69621469T2 (de) 1995-09-13 2002-12-12 Kyowa Hakko Kogyo Co., Ltd. Phenylpiperidin-derivate
WO1997040035A1 (en) 1996-04-19 1997-10-30 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
US6063796A (en) 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
AU732329B2 (en) 1997-05-30 2001-04-12 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivative
JPH10330377A (ja) 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
EP0921125B1 (en) 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
DK1049689T3 (da) * 1998-01-19 2002-07-22 Pfizer 4-(2-keto-1-benzimidazolinyl)piperidinderivater som ORL1-receptoragonister
WO1999048492A1 (en) 1998-03-26 1999-09-30 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
EP1080091A1 (en) 1998-05-18 2001-03-07 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
MA26659A1 (fr) * 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
NZ524681A (en) 2000-09-06 2005-09-30 Ortho Mcneil Pharm Inc A method for treating allergies using substituted pyrazoles

Also Published As

Publication number Publication date
US6872733B2 (en) 2005-03-29
AU2002338424B2 (en) 2005-04-21
ATE456564T1 (de) 2010-02-15
US20050192307A1 (en) 2005-09-01
EP2172468A1 (en) 2010-04-07
EP1975164B1 (en) 2010-01-27
JP4401076B2 (ja) 2010-01-20
DE60228072D1 (de) 2008-09-18
JP2004531532A (ja) 2004-10-14
EP1975164A2 (en) 2008-10-01
DK1975164T3 (da) 2010-05-25
DK1385518T3 (da) 2008-10-27
ES2312616T3 (es) 2009-03-01
PT1385518E (pt) 2008-10-07
CY1110000T1 (el) 2012-05-23
CA2444489C (en) 2010-06-22
CY1108456T1 (el) 2012-05-23
PT1975164E (pt) 2010-04-20
EP1385518A4 (en) 2005-10-05
ES2340441T3 (es) 2010-06-02
SI1385518T1 (sl) 2009-02-28
EP1385518A1 (en) 2004-02-04
EP1385518B1 (en) 2008-08-06
EP1975164A3 (en) 2008-10-08
US20030008886A1 (en) 2003-01-09
CA2444489A1 (en) 2002-10-31
WO2002085361A1 (en) 2002-10-31
SI1975164T1 (sl) 2010-05-31
DE60235274D1 (de) 2010-03-18

Similar Documents

Publication Publication Date Title
ATE403431T1 (de) Benzimidazolon-verbindungen
DE60229736D1 (de) Spiroinden- und spiroindan-verbindungen
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
DK1392642T3 (da) Hidtil ukendte forbindelser som anti-inflammatoriske, immunmodulatoriske og antiproliferative midler
DE60135387D1 (de) 7,9 substituierte tetracyclinverbindungen
DK1385515T3 (da) Spiropyrazole forbindelser
DE60214392D1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen
DE60039695D1 (de) Antifucoidan antikörper
EP1557407A4 (en) NEW ALPHA-CETOAMIDE DERIVATIVE AND USE THEREOF
ES2200689B1 (es) Compuestos de pirona y su uso.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1385518

Country of ref document: EP

REN Ceased due to non-payment of the annual fee